Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 17/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 16/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.40 |
| ▸ | USP2 | O75604 | 11/20 | 0.40 |
| ▸ | TSHR | P16473 | 7/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.38 |
| ▸ | CASP1 | P29466 | 4/20 | 0.38 |
| ▸ | CASP7 | P55210 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225370 | 0.89 | S1PR1 (0.58) | S1PR1ALDH1A1CYP1A2CYP3A4MAPK1 | |
| SCHEMBL2223368 | 0.87 | S1PR1 (0.83) | S1PR1ALDH1A1CYP1A2CYP3A4USP2 | |
| SCHEMBL2225593 | 0.86 | S1PR1 (0.52) | S1PR1ALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL14797011 | 0.83 | S1PR1 (0.82) | S1PR1ALDH1A1CYP1A2CYP3A4USP2 | |
| SCHEMBL2224650 | 0.81 | S1PR1 (0.58) | S1PR1ALDH1A1CYP1A2CYP3A4USP2 | |
| SCHEMBL14797147 | 0.81 | S1PR1 (0.67) | S1PR1ALDH1A1CYP1A2CYP3A4USP2 | |
| SCHEMBL2223316 | 0.80 | S1PR1 (0.75) | S1PR1ALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL2221025 | 0.80 | S1PR1 (0.83) | S1PR1ALDH1A1TSHRMAPK1HPGD | |
| SCHEMBL14797145 | 0.80 | S1PR1 (0.77) | S1PR1ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL2222826 | 0.79 | S1PR1 (0.73) | S1PR1ALDH1A1CYP1A2CYP3A4USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040544-B2 | 2,5-substituted oxazolopyrimidine derivatives | SANOFI (FR) | 2015-05-26 | — | — | US | claimed |
| EP-2523963-B1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES AS EDG-1 AGONISTS | SANOFI SA (FR) | 2014-08-27 | — | — | EP | claimed |
| US-20130072501-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2013-03-21 | — | — | US | claimed |
| EP-2523963-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2012-11-21 | — | — | EP | claimed |
| WO-2011086081-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | claimed |
| US-9040544-B2 | 2,5-substituted oxazolopyrimidine derivatives | SANOFI (FR) | 2015-05-26 | — | — | US | disclosed |
| EP-2523963-B1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES AS EDG-1 AGONISTS | SANOFI SA (FR) | 2014-08-27 | — | — | EP | disclosed |
| US-20130072501-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2013-03-21 | — | — | US | disclosed |
| EP-2523963-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086081-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072501-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | DPYD, CDK2, CCNT2 | S1PR1 1027/4885ALDH1A1 72/4885CYP1A2 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.